Recurrent Melanoma Completed Phase 1 Trials for Sirolimus (DB00877)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00655655Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsTreatment
NCT01522820Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsTreatment